Therapeutic Solutions International Inc (TSOI)

[centsability4me]

The NeuroStilbene Highway
or pipeline

where it came from :

the patent :

https://ih.advfn.com/p.php?pid=nmona&article=75866660

OCEANSIDE, CA--(iHub October 16, 2017) - Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the filing of an additional patent on the use of pterostilbene.

TSOI had previously announced the granting of U.S. Patent No.: 9,682,047 for our flagship product ProJuvenol® as an immuno-adjuvant to FDA approved chemotherapies and immunotherapies. In addition we have also filed an application with the U.S. Patent and Trademark Office for the means of augmenting circulating endogenous stem cells through administration of an effective amount of pterostilbene or derivatives thereof.

"Today's announcement of the filing of our third pterostilbene patent represents several years of research and literature review and was developed to utilize the ability of the immune system to augment the possibility of increasing overall survival of glioma patients after treatment with conventional therapies. Our data suggests that when pterostilbene is combined with brain cancer therapeutics such as Gefitinib, Sertraline, or Temozolomide, the prognosis is vastly improved", said co-inventor Timothy Dixon, President and CEO.

"What is particularly interesting is that pterostilbene appears to make cancer cells more visible to the immune system subsequent to their being attacked by conventional drug approaches", said Dr. Thomas Ichim, Board Member of TSOI and co-inventor of patent. "Specifically, we observed that this increase of immunogenicity that pterostilbene causes in chemotherapy treated cancer cells allows for enhanced immunity to cancer cells that have escaped chemotherapy, thus theoretically enhancing patient prognosis."

the product release :

http://ih.advfn.com/p.php?pid=nmona&article=77868683

Therapeutic Solutions International, Inc., Releases Intranasal Formulation of Pterostilbene for
Rapid Access to Blood-Brain Barrier

Company Expands its Pterostilbene Based Portfolio into Brain Cancers

Oceanside, CA -- July 16, 2018 -- Investorshub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the release of NeuroStilbene, a proprietary nano-formulation of pterostilbene formulated for intranasal delivery.

Intranasal delivery is used with the intention to deliver high concentrations of substances into the brain across what is called the "blood-brain barrier." This structure is a "security system" that keeps blood cells separate from the fluid surrounding the brain. This barrier does provide oxygen and nutrients to be transported by the blood cells but prevents harmful substances like bacteria or poisons from getting to the brain. While compounds such as pterostilbene [1,2], and alpha lipoic acid [3], can bypass the BBB, it is anticipated that higher concentrations can be delivered through the intranasal route.

"Our pharmacokinetic trial data showed a 55% increase in serum concentration of nanoparticle pterostilbene over a powdered and capsule form. We are therefore pleased to release a formulation of this product with double the potency and half-life over traditional powder formulation for intranasal use", said Timothy Dixon, President, and CEO. "Late last year we filed a patent on the synergistic inhibition of glioma using pterostilbene. Our data suggest that when pterostilbene is combined with brain cancer therapeutics such as Temozolomide, Sertraline, or Gefitinib, their prognosis is improved. Furthermore, we observed that pterostilbene causes an increase of immunogenicity in chemotherapy-treated cancer cells, providing heightened immunity to cancer cells that escaped chemotherapy, theoretically enhancing patient prognosis" added Mr. Dixon.

"The pterostilbene molecule has numerous potential applications in neurology and neuro-oncology. The generation of an intranasal formulation of pterostilbene opens the door for evaluating this molecule in a rapid manner in glioma and other brain cancer patients, where safe therapeutics with favorable safety profiles are urgently needed" said Dr. Santosh Kesari, MD, Ph.D., and member of the Company's Scientific Advisory Board.

"We are working on integrating NeuroStilbene into various protocols that are currently in development in order to enhance therapeutic options to patients with dreaded conditions such as brain tumors and neurodegenerative diseases" stated Dr. James Veltmeyer, Chief Medical Officer of the Company.

[1] Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Cancer Res. 2016 Sep 1; 76(17): 49704980. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010459/

[2] Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer. Int J Mol Sci. 2018 Jan 18;19(1). http://www.mdpi.com/1422-0067/19/1/287/pdf

[3] Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 1997;22(1-2):359-78. https://www.ncbi.nlm.nih.gov/pubmed/8958163

and now :

http://ih.advfn.com/p.php?pid=nmona&article=78119448

Therapeutic Solutions International Recruits NFL Chargers Hall of Famer Wes Chandler to Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football Players
Company to Advance NeuroStilbene Product for High-Performance Athletes
Susceptible to Head Injuries

Oceanside, CA -- August 22, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today recruitment of Wes Chandler to lead the development of its NeuroStilbene product for use in patients at risk of developing chronic traumatic encephalopathy (CTE).

Wes Chandler was a wide receiver in the National Football League (NFL) for eleven seasons during the 1970s and 1980s. He was selected to the Pro Bowl four times and ranked twelfth in NFL history in receiving yards and thirteenth in receptions when he retired. Chandler is a member of the San Diego Chargers Hall of Fame. He played college football for the Florida Gators and was also inducted into the College Football Hall of Fame in 2015.

CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

At a molecular level, it is known that CTE is associated with chronic activation of a cell type in the brain called the "microglia1". Studies have shown that pterostilbene, the active ingredient in NeuroStilbene, is capable of decreasing microglial activation, as well as reducing neuroinflammation, one of the major causes of CTE2.

"I have witnessed firsthand the devastation caused by CTE. I am very excited to work with TSOI at developing NeuroStilbene as an over the counter spray that is available for all athletes before exposure to activities where the risk of brain injury/concussions exists" stated Wes Chandler.

"We are very excited to work with Wes and the numerous colleagues and relations he has developed over the decades in professional sports, in order to provide solutions that not only prevent the onset of CTE but also in some cases reversing it, "said James Veltmeyer, MD, Chief Medical Officer of the Company.

"The formal launching of the CTE Program at TSOI is an indication of the breadth of different therapeutic indications that the pterostilbene molecule is capable of addressing," said Timothy Dixon, President, and CEO of the Company. "Given that NeuroStilbene is generated from ingredients that are Generally Regarded as Safe, the Company is capable of initiating sales of this product immediately, with confidence the market demand exists. We look forward to working with Wes and preventing and hopefully reversing this terrible condition.